Recommended

Discover how to overcome low affinity or poor TCR yields that are slowing you down in this upcoming webinar – register your details today
WEBINAR | Discover how advances can expand the possibilities for drug discovery, from target validation to preclinical development
Facing roadblocks in obesity drug discovery? Discover how integrated, validated strategies are helping teams accelerate development and reduce risk – register your details now
Unlock the science, strategy and real-world impact behind the next generation of precision therapies – access our new brand report now >>
Safety data is no longer just a regulatory checkbox – it’s a strategic advantage. Find out more in our upcoming webinar, register your details today
Explore how AI is reshaping early drug discovery, from target identification and compound screening to predictive modelling and trial design – register now!
news

Researchers develop CAR-T therapy that targets multiple leukaemia sites

A new CAR T-cell therapy has been created by researchers which targets three proteins on leukaemia cells and has shown success in pre-clinical trials.

Leukaemia cells

In a new pre-clinical study, a research team from Children’s Hospital Los Angeles, US, has engineered T cells to identify and target multiple sites on acute lymphoblastic leukaemia cells instead of just one. According to the scientists, the early collaboration points the way to future clinical trials to test the therapy.

Though most children with leukaemia respond well to chemotherapy, some experience resistant or relapsed disease, leading to the development of CAR-T therapy.

The therapy uses the patient’s T cells, isolating and genetically modifying them to recognise CD-19, a protein found on leukaemia cells. When the T cells are introduced back into the patient, the immune system attacks the cancer. Although initial treatment using CAR T offered meaningful results, nearly half of patients who receive this therapy later relapse because the cancer stops producing the protein CD-19 and becomes invisible to the T cells.

 

Reserve your FREE place

 


Are low affinity or poor TCR yields slowing you down?

Explore how CHO expression of soluble TCRs and TCR affinity maturation workflows via phage, serving as essential building blocks for early-stage TCR-TCE candidate generation.

22 October 2025 | 16:00 PM BST | FREE Webinar

Join Jiansheng Wu, Ph.D. to explore two integrated strategies:

  • High-titer CHO-based expression of sTCRs (~100 mg/L), enabling scalable and high-throughput production
  • Optimized phage display affinity maturation, improving TCR binding by up to ~10,000-fold

Whether you’re starting a new TCR program or optimizing an existing platform, this session will offer actionable strategies to accelerate discovery and improve candidate quality.

Register Now – It’s Free!

 

Lead investigator Dr Hisham Abdel-Azim collaborated with Dr Nabil Ahmed, of Baylor College of Medicine and Texas Children’s Hospital, both US, to engineer a T cell that targets not only CD19, but also two other proteins found on leukaemia cells, CD-20 and CD-22.

“It’s like using a trident to attack the cancer instead of a spear,” said Ahmed. The team used this three-pronged weapon against leukaemia cells in pre-clinical studies both in vitro and in an animal model and developed new methods to monitor how well it worked.

The new CAR T cells, named TriCAR T cells, target CD-19/20/22 and are significantly more effective than T cells that target CD-19 alone, according to the study’s findings. When the leukaemia cells stopped producing CD-19, the TriCAR T cells were still effective. “These newer CAR T cells bind to more cancer cells and these connections are much stronger,” explained Abdel-Azim. “Not only do they bind better, but they are binding again and again.”

The researchers highlight that although a clinical trial will be needed before the new CAR-T therapy could be used on patients, the early lab results point the way to a path that could be significantly more effective in battling resistant leukaemia.

The findings were published in Leukemia.